Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Cabinet minister warns of "concerning situation" as Omicron spreads

Sat, 11th Dec 2021 09:29

(Alliance News) - A booster dose sees the risk of symptomatic infection with the Omicron variant "significantly reduced", according to health officials who have urged all those eligible to make sure they get their third jab.

It comes as the experts warned the new variant could become the dominant strain in the UK by mid-December, with a Cabinet minister saying everything is being kept "under review" in terms of measures to tackle the spread.

Analysis by the UK Health Security Agency found that the AstraZeneca PLC and Pfizer Inc-BioNTech SE vaccines provided "much lower" levels of protection against symptomatic infection with Omicron compared to Delta.

But the preliminary data, which looked at 581 people with confirmed Omicron, suggested effectiveness seemed to "increase considerably" in the early period after a booster dose, giving around 70% to 75% protection against symptomatic infection.

The findings come as daily Covid-19 cases reached their highest level in almost a year and the UKHSA predicted that, if current trends continue, the UK will exceed one million infections by the end of the month.

Cabinet minister Michael Gove warned of a "deeply concerning situation" after holding a Cobra meeting on Friday afternoon to discuss the latest data and the co-ordinated response across the four nations.

The government said, as of 9 am on Friday, there had been a further 58,194 lab-confirmed Covid-19 cases in the UK.

The last time a higher daily figure was reported was on January 9, when 59,937 cases were recorded.

An additional 448 confirmed cases of the Omicron variant have been reported across the UK, bringing the total number to 1,265.

Mary Ramsay, head of immunisation at the UKHSA, said while their early data should be treated with caution, it indicates that "a few months after the second jab, there is a greater risk of catching the Omicron variant compared to Delta strain".

She added: "The data suggest this risk is significantly reduced following a booster vaccine, so I urge everyone to take up their booster when eligible."

Speaking to broadcasters, Gove said the Omicron variant is doubling every two to three days in England "and possibly even faster in Scotland".

He added that 30% of reported cases in London are the new variant, and warned that evidence suggests Omicron is "more likely" than past Covid variants to "potentially" lead to hospital admissions among the fully vaccinated.

Scotland's First Minister Nicola Sturgeon has warned of the possibility of a "tsunami of infections" from the new variant – and said she could not rule out more restrictions north of the border as a result.

But No 10 maintained that there were "no plans" to go further with measures in England, amid reports that proposals are being drawn up for a Plan C, featuring even tougher rules.

Gove said the current approach being taken is "proportionate", but acknowledged that "we absolutely do need to keep everything under review".

He said: "Action is absolutely required and, as new data comes in, we will consider what action we do require to take in the face of that data."

The Guardian reported that UK Health Secretary Sajid Javid had been given a presentation from the UKHSA earlier this week warning that even if Omicron leads to less serious disease than Delta, it still risks overwhelming the NHS with 5,000 people admitted to hospital a day.

It said the leaked advice said "stringent action" would be needed on or before December 18 if the variant's doubling time stays at 2.5 days, although the newspaper added that what such restrictions might entail were not set out other than to say measures that would bring the R number – representing the average number of people each Covid-19 positive person goes on to infect – below 1.

Professor Neil Ferguson, from Imperial College London, whose data was instrumental to the UK going into lockdown in March 2020, told The Guardian that projections suggest Omicron could "very substantially overwhelm the NHS, getting up to peak levels of admissions of 10,000 people per day".

He said such a figure could be reached "sometime in January" but added that it was based on assumptions around the variant's ability to get around existing protection, and the premise that it is similar to Delta in terms of the severity of disease it causes – something that is not yet known.

He said: "Even the best-case scenarios involve several-fold more admissions per day than we're getting at the moment – we are at about 700 right now."

New guidance expected to come into force from Wednesday will see care home residents allowed only three visitors and one essential care worker, as part of new measures to protect the sector from the spread of the new variant.

The Department of Health & Social Care said the move was "in order to balance the current Covid-19 risk and the need to keep people safe in line with clinical advice".

From Friday, in England the legal requirement to wear masks was extended to more indoor spaces including museums, galleries and community centres.

There will be a return to working from home guidance from Monday, and mandatory Covid passports for large venues from Wednesday.

The new regulations will be put to a debate and vote in the Commons next week – and with Labour's support they are certain to be approved despite the prospect of a large Conservative revolt.

Asked about the expected Tory rebellion, Gove said he is "confident" people will examine the proposals "seriously, soberly and thoughtfully", adding: "And I'm also confident people will conclude that, on balance, it is right to act."

By PA Reporters

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.